Azor

Azor is a prescription tablet that combines amlodipine and olmesartan medoxomil to treat high blood pressure (hypertension). It is used in adults who need stronger blood-pressure control than a single medicine can provide. The two ingredients relax and widen blood vessels, which lowers pressure and reduces strain on the heart.

Azor tablets contain two active substances: amlodipine (as amlodipine besylate) and olmesartan medoxomil. Tablets are available in fixed-dose strengths such as 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, plus standard tablet excipients.

• Route: oral (swallow tablets with water)
• Adult dose: 1 tablet once daily; common strengths include 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, or 10 mg/40 mg (amlodipine/olmesartan)
• Timing: take at the same time each day; may be taken with or without food
• Tablet handling: swallow whole; do not crush or chew unless your prescriber instructs otherwise
• Missed dose: take the missed tablet the same day when remembered; if it is near the next dose, skip the missed dose and continue as scheduled; do not take 2 tablets at once
• Duration: long-term treatment as prescribed; dose adjustments are made by the prescriber based on blood pressure response and tolerability

• Route: oral tablets
• Dose: 1 tablet containing amlodipine/olmesartan (e.g., 5 mg/20 mg to 10 mg/40 mg)
• Frequency: once daily
• Timing: with or without food, preferably same time each day
• Duration: continued daily for ongoing blood pressure control as directed by a prescriber
• Mechanism at the taken dose: amlodipine reduces calcium entry into vascular smooth muscle to dilate arteries; olmesartan blocks angiotensin II (AT1) receptors to reduce vasoconstriction and aldosterone-related salt and water retention

Azor is commonly prescribed for adults with uncontrolled hypertension. It is also used when target blood pressure was not reached with monotherapy (one medicine alone), for example when a patient did well on either a calcium channel blocker or an ARB but readings still stayed above goal.

Typical situations where clinicians move to a combination tablet include:

• Persistently elevated clinic or home readings despite adherence to one antihypertensive
• Needing a simpler regimen to improve day-to-day consistency
• Blood pressure that rises strongly in the early morning (a common pattern in practice)
• Coexisting cardiovascular risk factors where tighter control is preferred per guideline-based care

Azor treats hypertension by relaxing blood vessels and blocking angiotensin II effects. Azopt treats glaucoma by lowering intraocular pressure, and it contains brinzolamide, a carbonic anhydrase inhibitor used as an eye drop. The medicines are not interchangeable, and their risk checks are different because one acts systemically on blood pressure while the other acts locally in the eye.

• Skipping doses after a few “normal” readings, then doubling up later; this often triggers dizziness and doesn’t improve long-term control.
• Taking the tablet at random times each day; blood pressure medicines work best with steady daily timing.
• Using NSAIDs (ibuprofen, diclofenac) frequently for back pain without mentioning it; NSAIDs can raise blood pressure and stress kidney function when combined with ARBs.
• Adding potassium supplements or salt substitutes that contain potassium; ARBs can increase potassium, and the combination sometimes pushes levels too high.
• Chasing numbers with repeated measurements; taking five readings back-to-back can create anxiety and misleading averages.

In clinical practice, doctors often choose Azor when a patient’s readings improved on either a calcium channel blocker or an ARB but never reached target. The single-tablet combination can also help when adherence is the main obstacle, because two mechanisms are covered without adding another dosing time.

A common pattern with amlodipine-containing therapy is early ankle swelling or warmth/flushing in the first weeks. Some patients settle after the body adapts; others need a change in strategy if oedema becomes persistent. Dizziness is also reported early, especially in people who start therapy while dehydrated from fasting, intense exercise, or gastrointestinal illness, and a simple hydration check can prevent avoidable low-pressure episodes. Another real-world issue is that home blood pressure cuffs are sometimes the wrong cuff size; a cuff that is too small can over-read and push unnecessary dose escalation. WHO hypertension resources continue to stress accurate measurement technique as part of effective control, not just medication choice ^[4].